60 DEGREES PHARMACEUTICALS, INC. 8-K

What Happened

• 60 Degrees Pharmaceuticals, Inc. (SXTP) filed an 8-K (Feb 12, 2026) reporting that Nasdaq's Listing Qualifications Department had determined to delist the company's common stock and warrants for failing to maintain a minimum $1.00 bid price under Nasdaq Listing Rule 5550(a)(2).
• The Company paid a $20,000 hearing fee and appealed, which stayed the suspension of trading and the filing of Form 25-NSE. On February 11, 2026, Nasdaq notified the Company that it had regained compliance with the minimum bid price requirement; the February 19, 2026 hearing was cancelled and the matter is closed. The common stock will continue to be listed and traded on the Nasdaq Capital Market.

Key Details

• Nasdaq rule cited: Listing Rule 5550(a)(2) — minimum $1.00 bid price for 30 consecutive business days.
• Hearing fee paid by the company: $20,000.
• Regained compliance notification date: February 11, 2026.
• Scheduled Nasdaq Hearings Panel date cancelled: February 19, 2026; delisting action withdrawn/closed.

Why It Matters

• For investors, continuation of Nasdaq listing preserves liquidity, visibility, and access to institutional and retail trading that can be reduced if a security moves to OTC markets.
• The filing confirms the immediate risk of delisting has been removed based on Nasdaq's notice, but the company must maintain continued compliance with listing standards going forward.